001027019 001__ 1027019
001027019 005__ 20250204113901.0
001027019 0247_ $$2doi$$a10.1007/s00415-024-12378-1
001027019 0247_ $$2ISSN$$a0367-004X
001027019 0247_ $$2ISSN$$a0012-1037
001027019 0247_ $$2ISSN$$a0340-5354
001027019 0247_ $$2ISSN$$a1432-1459
001027019 0247_ $$2datacite_doi$$a10.34734/FZJ-2024-03585
001027019 0247_ $$2pmid$$a38656623
001027019 0247_ $$2WOS$$aWOS:001208272700002
001027019 037__ $$aFZJ-2024-03585
001027019 082__ $$a610
001027019 1001_ $$00000-0002-4429-0367$$aKohle, Felix$$b0$$eCorresponding author
001027019 245__ $$aRituximab in non-systemic vasculitic neuropathy: a single-center experience
001027019 260__ $$aHeidelberg$$bSpringer$$c2024
001027019 3367_ $$2DRIVER$$aarticle
001027019 3367_ $$2DataCite$$aOutput Types/Journal article
001027019 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721216946_1237
001027019 3367_ $$2BibTeX$$aARTICLE
001027019 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001027019 3367_ $$00$$2EndNote$$aJournal Article
001027019 500__ $$aFunding Open Access funding enabled and organized by Projekt DEAL. FK was supported by the Cologne Clinician Scientist Program (CCSP)/Faculty of Medicine/University of Cologne. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (Project No. 413543196).
001027019 520__ $$aObjectives This case series reports clinical features and outcome of four patients with non-systemic vasculitic neuropathy(NSVN) treated with the anti-CD20 agent rituximab.Methods Clinical, electrophysiological and biopsy data were retrospectively obtained and evaluated. Only patients withpathological definite or probable NSVN were included. Extensive clinical and laboratory work-up excluded systemic vasculitis.Follow-up data for at least 12 months and up to five years is provided. Outcome of the patients was assessed usingthe MRC-Sum Score, Prineas Score and Neurological Symptom Score.Results Two of four patients treated with rituximab achieved disease remission and one patient remained stable under anti-CD20 therapy after a required treatment switch due to toxic side effects of cyclophosphamide. One patient deteriorated underrituximab induction. Rituximab was well tolerated in all patients.Discussion Anti-CD20 therapy might be an alternative in NSVN patients requiring further treatment escalation or treatmentswitch due to side effects of corticosteroids or cyclophosphamide.
001027019 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001027019 536__ $$0G:(GEPRIS)413543196$$aDFG project 413543196 - Kölner Clinician Scientist Programm (413543196)$$c413543196$$x1
001027019 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001027019 7001_ $$0P:(DE-HGF)0$$aWunderlich, Gilbert$$b1
001027019 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b2
001027019 7001_ $$0P:(DE-HGF)0$$aSchroeter, Michael$$b3
001027019 7001_ $$0P:(DE-HGF)0$$aLehmann, Helmar C.$$b4
001027019 7001_ $$0P:(DE-HGF)0$$aSchneider, Christian$$b5
001027019 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-024-12378-1$$gVol. 271, no. 7, p. 4406 - 4411$$n7$$p4406 - 4411$$tJournal of neurology$$v271$$x0367-004X$$y2024
001027019 8564_ $$uhttps://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.pdf$$yOpenAccess
001027019 8564_ $$uhttps://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.gif?subformat=icon$$xicon$$yOpenAccess
001027019 8564_ $$uhttps://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
001027019 8564_ $$uhttps://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
001027019 8564_ $$uhttps://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
001027019 909CO $$ooai:juser.fz-juelich.de:1027019$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001027019 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b2$$kFZJ
001027019 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001027019 9141_ $$y2024
001027019 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
001027019 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
001027019 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
001027019 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
001027019 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001027019 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001027019 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-10$$wger
001027019 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
001027019 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
001027019 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2024-12-10
001027019 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-10
001027019 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-10
001027019 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
001027019 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
001027019 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
001027019 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
001027019 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2024-12-10
001027019 920__ $$lyes
001027019 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001027019 980__ $$ajournal
001027019 980__ $$aVDB
001027019 980__ $$aUNRESTRICTED
001027019 980__ $$aI:(DE-Juel1)INM-3-20090406
001027019 9801_ $$aFullTexts